To assess the utility of CD123 as a target for ALL in our system, we generated CD123-specific CAR T cells with the CD28 co-stimulatory domain, this time without the iCasp9 domain, since it was not needed to address this question. This evidence concerns the gene IL3RA and acute lymphoblastic leukemia.